Jefferies Group reiterated their buy rating on shares of TherapeuticsMD Inc (AMEX:TXMD) in a research report sent to investors on Tuesday morning, StockTargetPrices.com reports. The brokerage currently has a $18.00 target price on the stock.
Separately, Oppenheimer Holdings Inc. started coverage on shares of TherapeuticsMD in a research note on Tuesday, November 22nd. They issued an outperform rating on the stock.
TherapeuticsMD (AMEX:TXMD) opened at 7.10 on Tuesday. The company’s market cap is $1.40 billion. TherapeuticsMD has a 1-year low of $4.39 and a 1-year high of $11.26. The stock’s 50 day moving average price is $6.27 and its 200-day moving average price is $7.34.